

DAFTAR PUSTAKA

1. Özkan Y, Atay T, Dikmen N, İşimer A, Aboul-Enein HY. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with β -cyclodextrin. *Pharm Acta Helv.* 2000;74(4):365–70.
2. Maggi L, Canobbio A, Bruni G, Musitelli G, Conte U. Improvement of the dissolution behavior of gliclazide, a slightly soluble drug, using solid dispersions. *J Drug Deliv Sci Technol.* 2015;26:17–23.
3. Sarkar A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and pharmaceutical profile of gliclazide : A review. *J Appl Pharm Sci.* 2011;01(09):11–9.
4. Biswal S, Sahoo J, Murthy PN. Physicochemical properties of solid dispersions of gliclazide in polyvinylpyrrolidone K90. *AAPS PharmSciTech.* 2009;10(2):329–34.
5. Kimoto K, Suzuki K, Kizaki T, Hitomi Y, Ishida H, Katsuta H, et al. Gliclazide protects pancreatic β -cells from damage by hydrogen peroxide. *Biochem Biophys Res Commun.* 2003;303(1):112–9.
6. Dwichandra Putra O, Yonemochi E, Uekusa H. Isostructural Multicomponent Gliclazide Crystals with Improved Solubility. *Cryst Growth Des.* 2016;16(11):6568–73.
7. Chadha R, Raani D, Goyal P. Novel cocrystals of gliclazide: characterization and evaluation. *Cryst Eng Comm.* 2016;
8. Bruni G, Berbenni V, Maggi L, Mustarelli P, Friuli V, Ferrara C, et al. Multicomponent crystals of gliclazide and tromethamine: preparation , physico-chemical , and pharmaceutical characterization. *Drug Dev Ind Pharm.* 2018;44(2):243–50.
9. Henderik W. Frijlink, Eissens AC, Hefting NR, Poelstra K, Lerk CF, Meijer DKF. The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. *Pharm Res.* 1991;8(1):9–16.

- 
10. Shinde U, Nair U, Desai H, Martis E, Amin P. Cocrystals of gliclazide: formulation and characterisation. *Am J Pharmtech Res.* 2017;7(2).
 11. Grothe E, Meekes H, Vlieg E, Horst JH, Gelder R De. Solvates, salts, and cocrystals: A proposal for a feasible classification system. *Cryst Growth Des.* 2016;15:3237–43.
 12. Rowe RC, Sheskey PJ, Quinn ME, editors. *Handbook of Pharmaceutical Excipients*. Sixth Edit. Constitution Avenue, NW, Washington: Pharmaceutical Press and American Pharmacist Association; 2009. 431-432 p.
 13. Palmer KJ, Brogden RN. Gliclazide An Update of its pharmacological properties and therapeutic efficacy in non-insulin dependent diabetes mellitus. *Drugs*. 1993;46(1):92–125.
 14. British Pharmacopoeia Monograph: Medicinal and Pharmaceutical Substances. vols. I. UK: Medicines & Health Products Regulatory Agency; 2013. 1022-1023 p.
 15. Sweetman SC. *Martindale The Complete Drug Reference*. 36th ed. Sean C Sweetman, editor. London, UK: Pharmaceutical Press; 2009. 440 p.
 16. Winters CS, Shields L, Timmins P, York P. Solid-state properties and crystal structure of gliclazide. *J Pharm Sci.* 1994;83(3):300–4.
 17. Pfund LY, Chamberlin BL, Matzger AJ. The bioenhancer piperine is at least trimorphic. *Cryst Growth Des.* 2015;15:2047–51.
 18. Vasavirama K, Upender M. Piperine: A valuable alkaloid from piper species. *Int J Pharm Pharm Sci.* 2014;6(4).
 19. Chopra B, Nagar Y, Dhingra A, Prasad DN. Piperine and its various physicochemical and biological aspects: A review. *Open Chem J.* 2016;3:75–96.
 20. Wadhwa S, Singhal S, Rawat S. Bioavailability enhancement by piperine : A review. *Asian J Biomed Pharm Sci.* 2014;04(36):1–8.
 21. Mhaske D, Sreedharan S, Mahadik K. Role of piperine as an effective

- bioenhancer in drug absorption. *Pharm Anal Acta*. 2018;9(7):1–4.
22. Boger RH. The pharmacodynamics of L-arginine. *J Nutr*. 2007;1650–5.
 23. Shervington A, Tayyem R Al. Arginine. In: Analytical Profiles of Drug Substances and Excipients. 2001. p. 1–32.
 24. Budavari S. The Merck Index - An Encyclopedia of Chemical, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc.; 1996. 817 p.
 25. Dawn H, Clarke M. Crystal engineering of multi-component crystal forms: The opportunities and challenges in design. University of South Florida; 2012.
 26. Aaltonen J, Allesø M, Mirza S, Koradia V, Gordon KC, Rantanen J. Solid form screening – A review. *Eur J Pharm Biopharm*. 2009;71(1):23–37.
 27. Khankari RK, Grant DJW. Pharmaceutical hydrate. *Thermocimica Acta*. 1995;248:61–79.
 28. Wouters J, Quere L, editors. Pharmaceutical Salts and Co-crystals. Milton Road, Cambridge: The Royal Society of Chemistry; 2012.
 29. Pindelska E, Sokal A, Kolodziejski W. Pharmaceutical cocrystals , salts and polymorphs : Advanced characterization techniques. *Adv Drug Deliv Rev*. 2017;117:111–46.
 30. Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. *J Pharm Sci*. 1977;66(1):1–19.
 31. Hornedo NR, Nehm SJ, Jayasankar A. Cocrystals: Design, properties and formation mechanisms. In: Swarbrick J, editor. Encyclopedia of Pharmaceutical Technology. Third Edit. New York, USA: Informa Healthcare USA, Inc.; 2007.
 32. Kumar S, Nanda A. Pharmaceutical Cocrystal : An Overwiew. *Indian J Pharm Sci*. 2017;79(6).
 33. Gangadhar ZA, Bhaskar DA, Bhaskar GS, Bhanudas SR. Preparation and characterization of ibuprofen cocrystal by using *solvent drop grinding* method. *World J Pharm Res*. 2014;3(4):1392–402.

34. Miroshnyk I, Mirza S, Sandler N. Pharmaceutical co-crystals an opportunity for drug product enhancement. *Expert Opin Drug Deliv.* 2009;6(4):333–42.
35. Desiraju GR. Supramolecular synthons in crystal engineering-A new organic synthesis. *Angew Chemie Int Ed English.* 1995;34:2311–27.
36. Hemamalini M, Loh W, Quah CK, Fun H. Investigation of supramolecular synthons and structural characterisation of aminopyridine-carboxylic acid derivatives. *Chem Cent J.* 2014;8(31):1–9.
37. Maruyoshi K, Iuga D, Antzutkin ON, Alhalaweh A, Velaga SP, Brown SP. Identifying the intermolecular hydrogen-bonding supramolecular synthons in an indomethacin – nicotinamide cocrystal by solid-state NMR. *R Soc Chem.* 2012;48:10844–6.
38. Karagianni A, Malamatari M, Kachrimanis K. Pharmaceutical cocrystals: New solid phase modification approaches for the formulation of APIs. *Pharmaceutics.* 2018;10(18):1–30.
39. Yadav S, Gupta PC, Sharma N, Kumar J. Cocrystals: An alternative approach to modify physicochemical properties of drugs. *Int J Pharm Chem Biol Sci.* 2015;5(2):427–36.
40. Phadnis N V, Cavatur RK, Suryanarayanan R. Identification of drugs in pharmaceutical dosage forms by X-ray powder diffractometry. *J Pharm Biomed Anal.* 1997;15:929–43.
41. Vaghela P, Tank HM, Jalpa P. Cocrystals: A novel approach to improve the physicochemical and mechanical properties. *Indo Am J Pharm Res.* 2014;4(10):5055–65.
42. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. *Cryst Growth Des.* 2009;9(6):2950–67.
43. Saganowska P, Wesolowski M. Principal component and cluster analyses as supporting tools for co-crystals detection. *J Therm Anal Calorim.* 2017;130(1):45–55.
44. Aakero-y CB, Salmon DJ, Smith MM, Desper J. Cyanophenylloximes : Reliable

- and versatile tools for hydrogen-bond directed supramolecular synthesis of cocrystals. *Cryst Growth Des.* 2006;6(4):1033–42.
45. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: Importance and enhancement techniques. *Int Sch Res Netw Pharm.* 2012;2012:1–10.
 46. Jindal K. Review on solubility: A mandatory tool for pharmaceuticals. *Int Res J Pharm.* 2017;8(11):11–5.
 47. Farmakope Indonesia. Edisi V. Jakarta: Kementerian Kesehatan RI; 2014.
 48. Shargel L, Yu ABC, editors. *Applied Biopharmaceutics and Pharmacokinetics*. Seventh Ed. United States: The McGraw-Hill Companies, Inc; 2012.
 49. Convention U. P. *The United States Pharmacopeia/National Formulary*. In: R, Ockville M: USPC, editors. USP30/NF25. Maryland; 2011.
 50. Zaini E, Wahyuni YS, Halim A, Yuliandra Y. Preparation of eutectic mixture of ketoprofen and nicotinamide for enhanced dissolution rate. *Int J Pharm Sci Rev Res.* 2015;35(1):161–4.
 51. K KS, Sunita S. Design and development of fast dissolving tablet of gliclazide. *J Dev Drugs.* 2017;6(3).
 52. Vasavirama K, Upender M. Piperine: A valuable alkaloid from piper species. *Int J Pharm Pharm Scieences.* 2014;6(4):34–8.
 53. Mittapalli S, Mannava C, Khandavili R, Allu S, Nangia A. Soluble salts and cocrystals of clotrimazole. *Cryst Growth Des.* 2015;
 54. Thakuria R, Sarma B. Drug- drug and drug- nutraceutical cocrystal / salt as alternative medicine for combination therapy : A crystal engineering approach. *Crystals.* 2018;8(101):1–38.
 55. Akeroy CB, Fasulo ME, Desper J. Cocrystal or salt : Does it really matter ? *Mol Pharm.* 2007;4(3):317–22.
 56. Zaini E, Nisak RK, Utami RD, Fitriani L, Ismed F. Effect of milling on physicochemical properties of usnic acid isolated from Usnea sp . *Orient J*

- Chem. 2017;33(6):3031–6.
57. Zaini E, Halim A, Soewandhi SN, Setyawan D. Peningkatan laju pelarutan trimetoprim melalui metode kokristalisasi dengan nikotinamida. J Farm Indones. 2011;5(44):205–12.
 58. Zaini E, Shilvi A, Halim A. Studi sistem dispersi padat gliklazid menggunakan polivinil pirolidon K-30 (PVP K-30) dan tween 80. J Sains dan Teknol Farm. 2011;16(2):95–103.
 59. Weiss IM, Muth C, Drumm R, Kirchner HOK. Thermal decomposition of the amino acids glycine, cysteine, aspartic acid, asparagine, glutamic acid, glutamine, arginine and histidine. BMC Biophys. 2018;11(1):1–15.
 60. Wardiyah, Asyarie S, Wikarsa S. Pembuatan dan karakterisasi dispersi padat sistem biner dan terner dari gliklazid. Acta Pharm Indones. 2012;37(3):95–101.
 61. Mathias LJ. The glass transition [Internet]. Polymer Science Learning Center. [cited 2019 Jul 14]. Available from: <https://pslc.ws/macrog/tg.htm>
 62. Angell CA, Ngai KL, McKenna GB, McMillan PF, Martin SW. Relaxation in glassforming liquids and amorphous solids. J Appl Phys. 2000;88(6).
 63. Debenedetti PG, Stillinger FH. Supercooled liquids and the glass transition. Nature. 2001;410:259–67.
 64. Zaini E, Nofita R, Salman, Kurniati I. Karakterisasi fisikokimia dan laju disolusi dispersi padat ibuprofen dengan pembawa polietilenglikol 6000. J Ris Kim. 2010;4(1):25–31.
 65. Davis RE, Lorimer KA, Wilkowski MA, Rivers JH. Studies of Relationship in Cocrystal Systems. Am Crystallogr Assoc Trans. 2004;39:41–61.
 66. Cherukuvada S, Row TNG. Comprehending the formation of eutectics and cocrystals in terms of design and their structural interrelationships. Cryst Growth Des. 2014;14:4187–98.
 67. Gaur PK, Mishra S, Purohit S, Dave K. Transdermal drug delivery system: A review. Asian J Pharm Clin Res. 2009;2(1):14–20.

68. Zaini E, Putri VZ, Octavia MD, Ismed F. Peningkatan laju disolusi dispersi padat amorf genistein dengan PVP K-30. *J Sains Farm Klin.* 2017;4(1):67–72.
69. Karkhanis V V, Captain AD, Desai DC. Validation of UV Spectrophotometric method for estimation of Gliclazide in bulk and pharmaceutical formulation. *J Pharm Res.* 2012;5(2):1160–1.
70. G MC, S DP, P JN, O AB. Solubility and dissolution enhancement of gliclazide by solid dispersion technique. *Int J Pharm Chem Anal.* 2015;2(2):51–8.

